UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Purchases 2,774,933 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• UBS Asset Management has increased its stake in Arrowhead Pharmaceuticals by 138%, acquiring an additional 2,774,933 shares to hold a total of 4,785,062 shares worth approximately $60.96 million.
• Multiple institutional investors have shown interest in Arrowhead, with significant increases in holdings by firms like Goldman Sachs and ADAR1 Capital Management, indicating strong institutional backing for the stock.
• Analysts currently rate Arrowhead Pharmaceuticals with a consensus of "Buy" and a target price of $43.14, despite recent earnings missing expectations.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 138.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,785,062 shares of the biotechnology company's stock after purchasing an additional 2,774,933 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned about 3.46% of Arrowhead Pharmaceuticals worth $60,962,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. Empowered Funds LLC increased its holdings in Arrowhead Pharmaceuticals by 6.9% during the 1st quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company's stock worth $194,000 after purchasing an additional 979 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Arrowhead Pharmaceuticals by 34.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company's stock worth $22,189,000 after purchasing an additional 447,456 shares in the last quarter. Dynamic Technology Lab Private Ltd increased its holdings in Arrowhead Pharmaceuticals by 40.9% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 26,969 shares of the biotechnology company's stock worth $343,000 after purchasing an additional 7,827 shares in the last quarter. AQR Capital Management LLC bought a new position in Arrowhead Pharmaceuticals during the 1st quarter worth about $514,000. Finally, ADAR1 Capital Management LLC increased its holdings in Arrowhead Pharmaceuticals by 336.4% during the 1st quarter. ADAR1 Capital Management LLC now owns 56,300 shares of the biotechnology company's stock worth $717,000 after purchasing an additional 43,400 shares in the last quarter. Institutional investors own 62.61% of the company's stock.

Insider Transactions at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 15,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $25.00, for a total transaction of $375,000.00. Following the completion of the sale, the insider directly owned 247,122 shares in the company, valued at $6,178,050. This trade represents a 5.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have sold 25,000 shares of company stock worth $575,000 in the last three months. Company insiders own 4.30% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ARWR. TD Cowen upgraded Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, July 28th. Wall Street Zen cut Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, July 18th. Chardan Capital restated a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Monday, August 11th. HC Wainwright restated a "buy" rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, September 2nd. Finally, B. Riley upgraded Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, August 11th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $43.14.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR stock opened at $29.72 on Monday. The firm has a 50 day moving average price of $19.99 and a two-hundred day moving average price of $16.52. The company has a quick ratio of 4.87, a current ratio of 4.87 and a debt-to-equity ratio of 0.39. The company has a market capitalization of $4.11 billion, a PE ratio of -23.22 and a beta of 1.00. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $9.57 and a 12-month high of $31.13.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The business had revenue of $27.77 million for the quarter, compared to analysts' expectations of $29.01 million. During the same period in the previous year, the business earned ($1.38) EPS. As a group, analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.